Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q93811583)
Watch
English
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia
No description defined
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
title
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
main subject
prostatic hypertrophy
1 reference
based on heuristic
inferred from title
author name string
Claus G Roehrborn
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
1 January 2003
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
published in
Reviews in urology
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
volume
5 Suppl 5
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
page(s)
S12-21
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
cites work
Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Longitudinal changes in peak urinary flow rates in a community based cohort
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Health-related quality of life associated with lower urinary tract symptoms in four countries.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Steroid 5 alpha-reductase: two genes/two enzymes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Benign prostatic hyperplasia. Hormonal treatment.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
The development of human benign prostatic hyperplasia with age
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
High prevalence of benign prostatic hypertrophy in the community
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1502358
retrieved
11 February 2021
Identifiers
PMC publication ID
1502358
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
PubMed publication ID
16985965
1 reference
stated in
Europe PubMed Central
PMC publication ID
1502358
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1502358&resulttype=core&format=json
retrieved
10 May 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
